These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. TCT Daily: Cypher more effective for long lesions. J Interv Cardiol; 2007 Feb; 20(1):34. PubMed ID: 17300398 [No Abstract] [Full Text] [Related]
3. Understanding the drug-eluting stent trials. Coolong A; Kuntz RE Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349 [TBL] [Abstract][Full Text] [Related]
4. Sirolimus-eluting stents: does a great stent still need a good interventionalist? Carrozza JP J Am Coll Cardiol; 2004 Mar; 43(6):1116-7. PubMed ID: 15028376 [No Abstract] [Full Text] [Related]
5. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent. Beijk MA; Piek JJ Expert Rev Med Devices; 2007 Jan; 4(1):11-21. PubMed ID: 17187467 [TBL] [Abstract][Full Text] [Related]
6. [PTCA with drug eluting stent. 90% fewer restenoses in high risk patients]. MMW Fortschr Med; 2004 Aug; 146(33-34):53. PubMed ID: 15526636 [No Abstract] [Full Text] [Related]
7. Coronary bifurcation stenting. Current techniques, outcome and possible future developments. Melikian N; Airoldi F; Di Mario C Minerva Cardioangiol; 2004 Oct; 52(5):365-78. PubMed ID: 15514572 [TBL] [Abstract][Full Text] [Related]
9. [Sirolimus-eluting vs paclitaxel-eluting stents -- the trials confirm differences in clinical outcome]. Gil RJ Kardiol Pol; 2005 Nov; 63(5):574-6; discussion 577. PubMed ID: 16362868 [No Abstract] [Full Text] [Related]
10. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. Morice MC; Serruys PW; Barragan P; Bode C; Van Es GA; Stoll HP; Snead D; Mauri L; Cutlip DE; Sousa E J Am Coll Cardiol; 2007 Oct; 50(14):1299-304. PubMed ID: 17903626 [TBL] [Abstract][Full Text] [Related]
11. Drug-eluting stents: the panacea for restenosis? Lim MC Singapore Med J; 2004 Jul; 45(7):300-2. PubMed ID: 15221043 [No Abstract] [Full Text] [Related]
12. The impact of Sirolimus Eluting stents in interventional cardiology. Di Mario C; Griffiths H; O'Rourke B; Kaddoura S Int J Cardiol; 2004 Jun; 95(2-3):117-21. PubMed ID: 15193808 [No Abstract] [Full Text] [Related]
13. Is there a preferable DES in diabetic patients? A critical appraisal of the evidence. Byrne RA; Kastrati A Catheter Cardiovasc Interv; 2008 Dec; 72(7):944-9. PubMed ID: 19021280 [TBL] [Abstract][Full Text] [Related]
14. Coexistent in-stent restenosis, late incomplete stent apposition and mural thrombus in a zotarolimus-eluting stent. Zhang F; Qian J; Ge J J Invasive Cardiol; 2008 Aug; 20(8):423-5. PubMed ID: 18688068 [TBL] [Abstract][Full Text] [Related]
15. Comparison of bare-metal and sirolimus- or paclitaxel-eluting stents for aorto-ostial coronary disease. Barlis P; Kaplan S; Dimopoulos K; Ferrante G; Di Mario C Cardiology; 2008; 111(4):270-6. PubMed ID: 18451644 [TBL] [Abstract][Full Text] [Related]
16. Successful management of left main coronary artery stenosis with a paclitaxel-eluting stent in Takayasu's arteritis. Kang WC; Han SH; Ahn TH; Shin EK Int J Cardiol; 2006 Mar; 108(1):120-3. PubMed ID: 16516707 [No Abstract] [Full Text] [Related]
18. How many grails do we need? Holmes DR Circulation; 2004 May; 109(18):2158-9. PubMed ID: 15136508 [No Abstract] [Full Text] [Related]
19. Drug-eluting stents for chronic total occlusions make sense, but it is too early to close the discussion. Jørgensen E; Kelbaek H Eur Heart J; 2005 Jun; 26(11):1049-51. PubMed ID: 15821000 [No Abstract] [Full Text] [Related]
20. Angioscopic comparison of neointimal coverage between zotarolimus- and sirolimus-eluting stents. Awata M; Nanto S; Uematsu M; Morozumi T; Watanabe T; Onishi T; Iida O; Sera F; Kotani J; Hori M; Nagata S J Am Coll Cardiol; 2008 Aug; 52(9):789-90. PubMed ID: 18718430 [No Abstract] [Full Text] [Related] [Next] [New Search]